Searchable abstracts of presentations at key conferences in endocrinology

ea0032mte5 | (1) | ECE2013

Current guidelines for the classification of net

Rindi Guido

Neuroendocrine neoplasms (NENs) are a variety of neoplastic lesions distributed in most organs and apparata. The current World Health Organization (WHO 2010) introduced tumor grading (G1–G3) and tumour node metastasis (TNM) staging for class definition. The proposed grading system defines three classes (G1–G3) according to both mitotic count and Ki67 index. Three classes were defined as WHO class 1, neuroendocrine tumor (NET), G1; WHO class 2, NET G2 and WHO class 3,...

ea0035p551 | Endocrine tumours and neoplasia | ECE2014

Evaluation of vegf and endocan/esm-1 expression in pnets and correlation with Ki67 and prognosis

Lugli Francesca , Iacovazzo Donato , Lanza Paola , Inzani Frediano , Waure Chiara De , Rindi Guido , Marinis Laura De

Endocan has been reported as specific of endothelial tumor cells and was shown to be expressed by tip cells during angiogenesis process.The principal aims of the study are the assessment of immunohistochemical VEGF and Endocan expression in functioning and non functioning pNETs and the comparison of these markers with clinical features, Ki67 and TNM staging.We collected a total number of 79 pNETs surgical specimens for immunohistoc...

ea0052p26 | (1) | UKINETS2017

Multi-parametric assessment improves prognostication of small bowel neuroendocrine neoplasms: external validation of the NET nomogram

Clift Ashley , Faiz Omar , Martin John , Wasan Harpreet , Liedke Marc-Olaf , Schloericke Erik , Malczewska Anna , Rindi Guido , Kidd Mark , Modlin Irvin , Frilling Andrea

Background: Small-bowel neuroendocrine tumours (SB-NET) commonly metastasise despite most being low grade. The NET nomogram developed, estimates 5- and 10-year survival in SB-NET by allocating scores for 15 clinicopathological parameters. We comparatively evaluated the prognostic power of this nomogram, the WHO/ENETS grading and AJCC/UICC staging systems.Methods: Patients with histologically-confirmed SB-NET were identified from databases at two tertiary...

ea0090p409 | Pituitary and Neuroendocrinology | ECE2023

Inflammatory infiltrate in wild-type and non-wild-type GNAS somatotropinomas

Chiloiro Sabrina , Cicia Martina , Giampietro Antonella , Gessi Marco , Lauretti Liverana , Paolo Mattogno Pier , Carlino Angela , Olivi Alessandro , Rindi Guido , Pontecorvi Alfredo , De Marinis Laura , Doglietto Francesco , Bianchi Antonio

Introduction: Somatotropinomas are benign pituitary tumors with heterogeneous biological and clinical behavior. The tumor microenvironment (TME) is an environment generated by the interaction between tumor cells and the host immune system. It affects both the behavior of the tumor and the outcome of the therapy. The GNAS gene encodes the alpha subunit of G proteins associated with hormone receptors such as TSH, PTH, GHRH, FSH/lH, ACTH. Mutation of this gene has been associated...

ea0090p424 | Pituitary and Neuroendocrinology | ECE2023

The acro-TIME score: a new clinical, pathological and immune integrative approach to early identify acromegaly patients resistant to treatment with first generation somatostatin ligands

Chiloiro Sabrina , Giampietro Antonella , Gessi Marco , Lauretti Liverana , Mattogno Pierpaolo , Costanza Flavia , Carlino Angela , Olivi Alessandro , Rindi Guido , Pontecorvi Alfredo , De Marinis Laura , Doglietto Francesco , Bianchi Antonio

Somatotropinomas are benign pituitary tumors, with a heterogenous biological and clinical behavior. Tumor microenvironment reflects the interaction between tumor cells and the host immune system and may regulate tumor behavior and therapy outcome. We develop a scoring system that includes clinical, pathological and immune markers to early identify fg-SRLs resistant acromegaly pts. 43 acromegaly pts were included according the following criteria (1) first line treatment with su...

ea0090ep628 | Endocrine-related Cancer | ECE2023

Pancreas, An Unusual Metastatic Site In A Long-term Indolent Surviving Case, Under Somatostatin Analogues Therapy, Of Medullary Thyroid Carcinoma: A Case Report And Review Of Cases Documented In Literature

Raia Salvatore , Chiloiro Sabrina , Giampietro Antonella , Grazia Maratta Maria , Schinzari Giovanni , Attili Fabia , Gabriella Brizi Maria , Rufini Vittoria , De Marinis Laura , Pontecorvi Alfredo , Rindi Guido , Bianchi Antonio

Medullary thyroid carcinoma (MTC) accounts for 1%–2% of thyroid cancers and has a variable clinical course. MTCs present with locoregional metastasis in 50% of patients and distant metastasis in 10% to 15% at the time of initial diagnosis. The lungs, liver, and bone are common metastatic sites, and distant metastasis is known to be a poor prognostic factor for long-term oncologic outcomes. We present the long course case, under somatostatin analogues (SSA) therapy, of a 7...

ea0035p549 | Endocrine tumours and neoplasia | ECE2014

Efficacy of lanreotide autogel in men1-related gastrinomas: a case series

Iacovazzo Donato , Lugli Francesca , Bianchi Antonio , Capoluongo Ettore , Lucci-Cordisco Emanuela , Persiani Roberto , Doglietto Giovanni Battista , Pontecorvi Alfredo , Rindi Guido , De Marinis Laura

GEP NETs, especially gastrinomas, occur in 40–70% of MEN1 patients and represent the main cause of death in these patients.We aim to investigate the efficacy of lanreotide autogel (ATG) in the treatment of MEN1-related gastrinomas.We report a monocentric series of seven MEN1 patients (three M, and four F) treated with lanreotide ATG (120 mg/4 weeks) for a mean period of 62.1 months. Plasma gastrin levels have been measured at ...

ea0035p578 | Endocrine tumours and neoplasia | ECE2014

Antiproliferative effects of lanreotide Autogel in patients with enteropancreatic neuroendocrine tumours: results of CLARINET, a large international phase 3 study

Caplin Martyn , Ruszniewski Philippe , Pavel Marianne , Cwikla Jaroslaw , Phan Alexandria , Raderer Markus , Sedlackova Eva , Cadiot Guillaume , Wall Lucy , Rindi Guido , Langley Alison , Blumberg Joelle

Introduction: Data demonstrating antiproliferative effects of somatostatin analogs (SSAs) in enteropancreatic NETs are limited; only one prospective trial so far has shown this for patients with midgut tumors and low hepatic tumor load (HTL). CLARINET is the first large phase 3, randomized, placebo-controlled trial evaluating such effects for the SSA lanreotide in patients with non-functioning enteropancreatic NETs.Methods: Patients who had well/moderate...

ea0032p532 | Endocrine tumours and neoplasia | ECE2013

Pituitary transforming gene 1 (PTTG1) expression in seminoma

Milardi Domenico , Grande Giuseppe , Pierconti Francesco , Martini Maurizio , Cenci Tonia , Gulino Gaetano , Schinzari Giovanni , Larocca Luigi Maria , Rindi Guido , Pontecorvi Alfredo , De Marinis Laura

Pituitary transforming gene 1 (PTTG1) is a mammalian securing involved in mitosis to ensure chromosomal stability. PTTG1 is overexpressed in a variety of tumors. It can directly and indirectly induce expression of genes that are involved in regulating tumorigenesis and cancer development (c-Myc, bFGF, VEGF and MMP2).We evaluated PTTG1-expression by immunohistochemistry on formalin-fixed and paraffin-embedded specimen testicular tissues from 53 male patie...

ea0032p561 | Endocrine tumours and neoplasia | ECE2013

Everolimus treatment in a series of patients with advanced neuroendocrine tumors

Iacovazzo Donato , Lugli Francesca , Plastino Francesca , Schinzari Giovanni , Bianchi Antonio , Fusco Alessandra , Rindi Guido , Pontecorvi Alfredo , De Marinis Laura , Barone Carlo Antonio Mario

Introduction: Everolimus is an oral mTOR inhibitor that exerts antineoplastic effects inhibiting cell proliferation, survival and angiogenesis. Its activity in advanced neuroendocrine tumors (NETs) has been demonstrated in controlled trials and everolimus was approved by the FDA for the treatment of progressive, advanced pNETs in May 2011.Materials and methods: We treated with everolimus, at the dosage of 10 mg once daily, 14 patients with advanced, prog...